Research Article - Journal of Clinical and Bioanalytical Chemistry (2021) Volume 5, Issue 4
Favipiravir is a broad spectrum antiviral prescription famouus to selectivity block RNA-Dependent RNA Polymerase (RDRP) and sars-COVID-19.
Background: This study was aimed at assessing the magnitude of induced abortion and associated factors among students in Hawassa University, southern region, Ethiopia, 2019. Research and Methods: Favipiravir (6-fluoro-3-hydroxy-2-pyrazinecarboxamide), or else known as “T-705, or Avigan” has shown enormous covenant of antiviral activity against many of RNA viruses. Scientists have conducted rigorous studies on its antiviral properties against wide range of RNA viruses such as influenza, West Nile, and Ebola viruses together in vitro and in vivo. Yet, favipiravir has also enthused hopes that it may provide humankind with a broad spectrum of antivirals which may have a lesser amount of toxicity and elevated potency at little doses. India-based Glenmark Pharmaceuticals has reported constructive top-line data from a Phase III clinical trial of its favipiravir nonspecific FabiFlu to delicacy mild to moderate COVID-19.Author(s): A Mohamed Sikkander*